The role and efficacy of Tisotumab vedotin-tftv

Patients with cervical cancer have few treatment options if their cancer comes back or spreads after initial treatment. Tisotumab vedotin-tftv reduced the risk of death by 30% compared with chemotherapy in patients with recurrent or metastatic cervical cancer who had disease progression during or after first-line treatment, according to results from the phase 3 innovaTV 301 randomized global trial. This was a statistically significant and clinically meaningful reduction in the risk of death.

Vitin-Tesotuzumab demonstrates results compared to chemotherapy on primary and key secondary efficacy endpoints Showing a statistically significant extension of overall survival (OS) with Vitin-Tesotuzumab, demonstrating a 3-fold reduction in the risk of death compared with chemotherapy 0%; progression-free survival (PFS) results with Vitin-tisotuzumab reduced the risk of disease progression or death by 33% compared with chemotherapy; confirmed objective response rate (ORR) also had a statistically significant improvement; odds ratio was 4.0. And all complete responses, defined as patients with no detectable evidence of tumor at the designated time, were seen in the Vitin-tisotuzumab group. Disease control rate (DCR), defined as the percentage of patients who achieved complete response, partial response, or stable disease, was 75.9% in the vitin-tisotumab group.

Vitin-TisotumabThe original drug has not yet been marketed in China, so it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.